Mutant C/EBPα p30 alleviates immunosuppression of CD8(+) T cells by inhibiting autophagy‐associated secretion of IL‐1β in AML

OBJECTIVES: Mutant C/EBPα p30 (mp30), the product of C/EBPα double mutations (DM), lacks transactivation domain 1 and has C‐terminal loss‐of‐function mutation. Acute myeloid leukaemia (AML) patients harbouring C/EBPα DM could be classified as a distinct subgroup with favourable prognosis. However, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jun‐Dan, Xu, Jue‐Qiong, Zhang, Xue‐Ning, Huang, Ze‐Wei, Liu, Ling‐Ling, Zhang, Ling, Lei, Xin‐Xing, Xue, Man‐Jie, Weng, Jian‐Yu, Long, Zi‐Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715362/
https://www.ncbi.nlm.nih.gov/pubmed/36124714
http://dx.doi.org/10.1111/cpr.13331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715362/
https://www.ncbi.nlm.nih.gov/pubmed/36124714
http://dx.doi.org/10.1111/cpr.13331

Ejemplares similares